Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
Status:
Completed
Trial end date:
2021-04-06
Target enrollment:
Participant gender:
Summary
This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of
topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed
treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study
DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety
follow-up period.